RxDoctor Payments Data

Marshall Silverman, MD

Internal Medicine · Charlotte, NCNPI 1669435749

Payments from drug & device makers

$4,969in general payments, 2019–2025

Across 284 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$773
  • Novo Nordisk$716
  • Amgen$383
  • Pfizer$330
  • AstraZeneca$276
  • Lilly USA, LLC$195
  • plus $2K from 46 others

What the payments were for

  • Travel & lodging$2134%
  • Food & beverage$4,75696%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,969 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$74,762
Medicare patients
124
Services billed
1,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$49,014
MounjaroTirzepatide31$37,038
OzempicSemaglutide31$28,699
XareltoRivaroxaban26$28,312
GemtesaVibegron33$18,641
JardianceEmpagliflozin11$8,221
Doxepin Hcl12$4,404
Humalog Kwikpen U-100Insulin Lispro13$3,801
ArexvyRsvpref3 Antigen/As01e/Pf11$3,344
SynthroidLevothyroxine Sodium36$3,295
ZypitamagPitavastatin Magnesium13$2,655
Vilazodone Hcl42$2,459
Atorvastatin Calcium150$1,678
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide27$1,568
Boostrix TdapDiphth,pertuss(Acell),tet Vac19$1,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$330$49,01445 claims
Lilly USA, LLCMounjaro$195$37,03831 claims
Novo NordiskOzempic$716$28,69931 claims
Johnson & JohnsonXarelto$41$28,31226 claims
Sumitomo Pharma America, Inc.Gemtesa$73$18,64133 claims
Boehringer IngelheimJardiance$40$8,22111 claims
GSKArexvy$189$3,34411 claims
AbbVieSynthroid$773$3,29536 claims
Medicure Pharma Inc.Zypitamag$17$2,65513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →